Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17411801 | 1.00 | IGF1R (0.66) | IGF1RINSR | |
| SCHEMBL18836349 | 1.00 | IGF1R (0.66) | IGF1RINSR | |
| SCHEMBL18836198 | 0.99 | IGF1R (0.64) | IGF1RINSR | |
| SCHEMBL18836650 | 0.99 | IGF1R (0.64) | IGF1RINSR | |
| SCHEMBL17411462 | 0.99 | IGF1R (0.64) | IGF1RINSR | |
| SCHEMBL18836195 | 0.91 | IGF1R (0.57) | IGF1RINSR | |
| SCHEMBL18836432 | 0.91 | IGF1R (0.57) | IGF1RINSR | |
| SCHEMBL18836194 | 0.91 | IGF1R (0.57) | IGF1RINSR | |
| SCHEMBL17397468 | 0.91 | IGF1R (0.52) | IGF1RINSR | |
| SCHEMBL17397470 | 0.91 | IGF1R (0.52) | IGF1RINSR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170137410-A1 | FUSED CYCLOALKYL-PYRIMIDINE COMPOUNDS AND USES THEREOF | MEDIVATION TECHNOLOGIES, INC (US) | 2017-05-18 | — | — | US | claimed |
| US-20170137410-A1 | FUSED CYCLOALKYL-PYRIMIDINE COMPOUNDS AND USES THEREOF | MEDIVATION TECHNOLOGIES, INC (US) | 2017-05-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170137410-A1 | FUSED CYCLOALKYL-PYRIMIDINE COMPOUNDS AND USES THEREOF | DCK, DTYMK, TK1 | IGF1R 2770/4885INSR 2102/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.